BioPharmSignal logoBioPharmSignal

Biotech News

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

Synlogic (SYBX)SynlogicEarnings

CAMBRIDGE, Mass. , March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023 .

Open original release

Related news

SYBXSynlogic2024-11-12 21:35 EST

Synlogic Reports Third Quarter 2024 Financial Results

SYBXSynlogic2024-08-08 11:00 EST

Synlogic Reports Second Quarter 2024 Financial Results

VANIVivani Medical2026-03-26 20:16 EST

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MISTMilestone Pharmaceuticals Inc.2026-03-20 11:55 EST

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

MISTMilestone Pharmaceuticals Inc.2026-03-12 12:00 EST

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

MLYSMineralys Therapeutics2026-03-09 12:00 EST

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

ALGSAligos Therapeutics2026-03-05 13:00 EST

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

MNKDMannKind2026-02-26 13:00 EST

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MNKDMannKind2026-02-18 14:00 EST

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

CVRXCVRx2026-02-12 21:05 EST

CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

View all latest news

Synlogic

Synlogic was a synthetic-biology company focused on engineered microbes and metabolic disease before its restructuring and decline. Its platform aimed to use living medicines to address rare disorders.

Recent company news

SYBXSynlogic2024-11-12 21:35 EST

Synlogic Reports Third Quarter 2024 Financial Results

SYBXSynlogic2024-08-08 11:00 EST

Synlogic Reports Second Quarter 2024 Financial Results

SYBXSynlogic2024-05-14 11:00 EST

Synlogic Reports First Quarter 2024 Financial Results

SYBXSynlogic2024-03-19 11:00 EST

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

SYBXSynlogic2024-02-20 17:15 EST

Synlogic Adopts Limited Duration Stockholders Rights Plan

Stock data

Close
0.67 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States